Ask AI
ProCE Banner Activity

Patient Resource: Understanding Therapy Options for Your CLL/SLL

PDF

Download this interactive PDF developed in partnership with the CLL Society to increase your understanding of treatment options for your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and key factors that influence choice of therapy. 

Released: April 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the CLL Society

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

CLL Society

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of community hematologists/oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who are part of the multidisciplinary care team for people with R/R CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences leveraging novel targeted and/or cellular therapies for eligible patients with R/R CLL to optimize clinical benefit and quality of life in alignment with patient preferences, clinical evidence, and current guidelines

  • Employ guideline- and expert-recommended biomarker testing to assess patients with R/R CLL for acquired resistance mutations to guide therapy selection and optimal sequencing

  • Assess emerging clinical evidence for novel targeted and cellular therapies and the clinical implications for management of R/R CLL

  • Apply shared decision-making and communication strategies to support patient quality of life and engagement in care for R/R CLL

Disclosure

Primary Author

Nitin Jain, MD: researcher: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Pharmacyclics, Precision Biosciences, Sana Biotechnology, Takeda, Triarm, Ubix; consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB.

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Genentech, Johnson & Johnson, Loxo/Lilly, Merck, Newave, Schrödinger.